Inpharma

Oral misoprostol for PPH in resource-poor communities
pp. 1-1(1)

NICE recommends rituximab for follicular lymphoma . . .
pp. 2-2(1)

GlaxoSmithKline (GSK) has announced it is to provide antiretrovirals to Russia at a discount
pp. 2-2(1)

According to a Congressional Budget Office working paper, "excess" growth in US Medicare spending per beneficiary has slowed greatly over recent years
pp. 3-3(1)

Opioids alter surgical examination findings but not outcomes
pp. 3-3(1)

The issue of Plan B's contraceptive mechanism
pp. 3-3(1)

Limited correlation between animal and human study successes
pp. 3-3(1)

Institute of Medicine recommends US FDA reforms
pp. 4-4(1)

Rates of GnRH agonist use variable in prostate cancer
pp. 4-4(1)

Tiotropium bromide cost effective for COPD in Spain
pp. 4-4(1)

ICD therapy economically attractive in patients with stable HF
pp. 5-5(1)

Omega-3 ethylester concentrate saves costs in the long run
pp. 5-5(1)

Varicella zoster vaccine worth the cost?
pp. 5-5(1)

Joint crisis plans for the management of psychotic disorders are probably more cost effective than standardised service information
pp. 6-6(1)

Treatment with long-acting risperidone injection is not associated with reductions in hospital stay or resource use
pp. 6-6(1)

Recommended vaccines underused in IBD
pp. 6-6(1)

A combination of gemcitabine with ascorbic acid [vitamin C] and menadione [vitamin K3] is potentially more effective in treating urothelial cancer
pp. 6-6(1)

Elvucitabine appears to have potential for treating patients with HIV infections
pp. 6-6(1)

Ceftaroline a strong competitor in cSSSI
pp. 7-8(2)

Intrathecal triamcinolone is more beneficial than IV mitoxantrone for the treatment of chronic progressive multiple sclerosis (MS)
pp. 8-8(1)

Topical retapamulin comparable to cefalexin for skin infections
pp. 8-8(1)

Cognitive effects of insulin lead to good ideas for treatment
pp. 9-9(1)

A ragweed Toll-like-receptor-9-agonist vaccine is effective long-term for patients with allergic rhinitis
pp. 9-9(1)

Terazosin may be a beneficial treatment for women with bladder outlet obstruction
pp. 9-9(1)

Controlled-release prednisone is superior to immediate-release prednisone for reducing morning stiffness in rheumatoid arthritis
pp. 9-9(1)

Presumptive treatment of `service women' with azithromycin reduces the prevalence of cervical infections
pp. 10-10(1)

Candesartan cilexetil improves cardiac outcomes in patients with end-stage renal disease receiving haemodialysis
pp. 10-10(1)

Menthol may improve swallowing reflex times in elderly patients with dysphagia
pp. 10-10(1)

Inhaled liposomal amphotericin B prevents invasive aspergillosis
pp. 10-10(1)

DMXAA [AS 1404] extends survival in patients with non-small cell lung cancer
pp. 10-10(1)

Ozarelix may be an effective treatment for benign prostatic hyperplasia
pp. 10-10(1)

Trial ALERTs to boosting fosamprenavir with reduced ritonavir
pp. 11-12(2)

Topiramate reverts chronic migraine to episodic migraine in patients with medication overuse
pp. 12-12(1)

Midazolam provides superior tracheal intubating conditions to lidocaine
pp. 12-12(1)

A dronabinol/cannabidiol oromucosal spray improves spasticity and urinary incontinence in patients with multiple sclerosis
pp. 12-12(1)

ACE inhibitors and ARBs look promising for diabetes prevention
pp. 13-13(1)

Oxybutynin may be effective in generalised hyperhidrosis
pp. 13-13(1)

A combination of atazanavir, ritonavir and efavirenz has strong antiretroviral activity, but is associated with increased triglyceride levels
pp. 13-13(1)

Adjunctive therapy with galantamine improves attention and memory in patients treated with risperidone for schizophrenia
pp. 13-13(1)

Interferon alfacon-1 in combination with ribavirin has strong antiviral activity in patients with treatment-refractory hepatitis C
pp. 13-13(1)

Adalimumab superior to methotrexate for psoriasis
pp. 13-13(1)

Best to get in quick for eptifibatide benefits in myocardial infarction
pp. 14-14(1)

Baseline QOL predicts QOL following HAART initiation
pp. 14-14(1)

Oral tramadol/paracetamol plus periprostatic lidocaine decreases pain caused by transrectal ultrasound prostate biopsy
pp. 14-14(1)

Carvedilol enhances cilazapril or enalapril treatment for cardiac dysfunction in patients with muscular dystrophy
pp. 14-14(1)

Novel triple combo provides added benefit in advanced breast cancer
pp. 15-16(2)

Rivastigmine beneficial for memory after brain injury
pp. 16-16(1)

Paroxetine holds off effects of PE better than dapoxetine
pp. 16-16(1)

Rosuvastatin every other day still keeps cholesterol at bay
pp. 17-17(1)

Finasteride increases sensitivity of PSA for cancer detection
pp. 17-17(1)

Pramipexole to treat restless legs syndrome (RLS) results in QOL improvements that remain at 1 year
pp. 17-17(1)

Switching to a three nucleoside reverse transcriptase inhibitor (NRTI) regimen from protease inhibitor (PI)-based HAART is beneficial in children with HIV
pp. 17-17(1)

Topical rotigotine effectively improves symptoms in patients with moderate-to-severe restless legs syndrome
pp. 17-17(1)

Levosalbutamol effective for treatment of COPD
pp. 18-18(1)

The "coadministration of rofecoxib and tizanidine is best avoided"
pp. 18-18(1)

Lopinavir/ritonavir reduces the availability of lamotrigine in healthy subjects
pp. 18-18(1)

Caffeine appears to increase the rate of onset of levodopa benefits for patients with idiopathic Parkinson's disease
pp. 18-18(1)

Resveratrol effectively inhibits platelet aggregation in high-risk cardiac patients with aspirin resistance
pp. 18-18(1)

Low-dose aspirin increases risk of major haemorrhages
pp. 19-19(1)

Quinapril, but not enalapril, decreases inflammatory markers while improving endothelial function in patients with impaired cardiac function
pp. 19-19(1)

COX-2 inhibitors: `risk-inducing' effect at higher doses
pp. 19-19(1)

Neuropathy with leflunomide reported to ADRAC
pp. 20-20(1)

Current NSAID use associated with a modest increase in MI risk
pp. 20-20(1)

Blockbuster forecasts in psoriasis, AF markets
pp. 21-21(1)

ADRAC monitors reports of depression with ezetimibe
pp. 21-21(1)

Iodinated contrast media-related anaphylaxis: is prevention useful?
pp. 21-21(1)

US product approvals
pp. 22-22(1)

EU product approvals
pp. 22-22(1)

Other US regulatory news
pp. 22-22(1)

Product launches in Japan
pp. 22-22(1)

Metformin/pioglitazone [Competact] has been launched in the UK by Takeda for the treatment of type 2 diabetes mellitus
pp. 22-22(1)

Abbott has announced the international launch of its everolimus-eluting coronary stent system [Xience V].
pp. 23-23(1)

Health Canada has granted approval to Biogen Idec and Elan Corporation for natalizumab [Tysabri]
pp. 23-23(1)

China Pharma Holdings has received approval from the Chinese State FDA to manufacture and market its granisetron injection product.
pp. 23-23(1)

The Japanese Ministry of Health, Labour and Welfare has approved ketotifen [Pabron] as an OTC treatment for allergic rhinitis.
pp. 23-23(1)

The UK MHRA has requested additional information from York Pharma
pp. 23-23(1)